

ASX Release

10th November 2014

APPROVAL RECEIVED FROM ROYAL ADELAIDE HOSPITAL RESEARCH ETHICS COMMITTEE TO CONTINUE WITH CANCER TRIAL

PharmAust Limited (“PharmAust”) (ASX: PAA & PAAO) is pleased to report that further to its announcement on 21st October 2014, it has now received formal approval from the Royal Adelaide Hospital Research Ethics Committee to continue with its trial with PPL-1 in late stage human cancer patients.

Principal Investigator, Professor Michael Brown with support from CMAX will re-initiate screening to identify patients for the trial. It has also been confirmed that the first patient treated in the trial will be “replaced” by the next patient recruited, thus enabling three patients to be recruited and treated with the lowest dose of PPL-1 for 28 days, as specified in the protocol.

PharmAust’s Executive Chairman, Dr Roger Aston said, “This is a reassuring outcome and we look forward to continuing with assessment of PPL-1 in this “first in man” trial. Furthermore, we will report as soon as the next patient begins treatment with PPL-1. The drug will be potentially administered to patients suffering from diverse cancers. Recruitment will include selection of patients suffering from lung, pancreas, oesophageal, gastric, colorectal, ovarian, breast, prostate, liver, sarcoma, lymphoma, and melanoma”

The cancer chemotherapy market (estimated at \$42 billion/annum)* is currently the fastest growing sector within the pharma industry, mainly driven by the identification of new potential therapeutic targets. This growth is further fuelled by the magnitude of the disease worldwide, currently estimated at more than 25 million people suffering from cancer globally, and an estimated 5 million people dying each year from the disease.

*Reference: Research and Markets.com accessed 14th February 2014:

http://www.researchandmarkets.com/reports/335548/chemotherapy_market_insights_20062016_a

For further details please contact:

Dr Roger Aston
Executive Chairman
PharmAust Limited
Tel: 0402 762 204
www.pharmaust.com